Karen MBA - Poseida Therapeutics Senior Development
| PSTXDelisted Stock | USD 9.50 0.08 0.84% |
Executive
Karen MBA is Senior Development of Poseida Therapeutics
| Phone | 858 779 3100 |
| Web | https://poseida.com |
Poseida Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1311) % which means that it has lost $0.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5763) %, meaning that it created substantial loss on money invested by shareholders. Poseida Therapeutics' management efficiency ratios could be used to measure how well Poseida Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Poseida Therapeutics currently holds 85.42 M in liabilities with Debt to Equity (D/E) ratio of 1.39, which is about average as compared to similar companies. Poseida Therapeutics has a current ratio of 3.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Poseida Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Caitlin MBA | Generation Bio Co | N/A | |
| Emiko Bryant | PepGen | N/A | |
| Amy Reilly | Dyne Therapeutics | 51 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| John MBA | Dyne Therapeutics | 62 | |
| MS BS | Lantern Pharma | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Stefan Abele | Pharvaris BV | 55 | |
| Lily Cheung | Pliant Therapeutics | 52 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Jasmin Tower | Generation Bio Co | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Morgan Conn | Century Therapeutics | 56 | |
| Sara Besten | Generation Bio Co | N/A | |
| MBA CFA | PepGen | N/A | |
| Johanna FriedlNaderer | Dyne Therapeutics | 57 | |
| MBA MD | Dyne Therapeutics | 58 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Eric MD | Pliant Therapeutics | 61 | |
| Nicole Leber | Lantern Pharma | N/A | |
| Mary DeLena | PepGen | N/A | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 |
Poseida Therapeutics Leadership Team
Elected by the shareholders, the Poseida Therapeutics' board of directors comprises two types of representatives: Poseida Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poseida. The board's role is to monitor Poseida Therapeutics' management team and ensure that shareholders' interests are well served. Poseida Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poseida Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Loren Wagner, Senior Operations | ||
| Sarah Thailing, Senior IR | ||
| JD Esq, Chief Counsel | ||
| Johanna CPA, Chief Officer | ||
| Kristin Martin, Chief Officer | ||
| Alexander Chapman, Senior Communications | ||
| Karen MBA, Senior Development | ||
| Brent Warner, President Therapy | ||
| Mark JD, Executive Board | ||
| Devon Shedlock, Chief Therapy | ||
| Lisa Portale, Senior Affairs | ||
| Kristin Yarema, CEO President | ||
| Dr JD, Senior Counsel |
Poseida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poseida Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 777.81 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 58.44 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | 214.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Poseida Stock
If you are still planning to invest in Poseida Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poseida Therapeutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |